Now this is what you call market timing.
Life sciences hedge fund EcoR1 Capital disclosed that as of September 22 it had initiated a stake of nearly 5.75 million shares of Mirati Therapeutics, making it the second-largest shareholder, with about 9.8 percent of the commercial-stage oncology company’s shares.
